Molecular biology and cancer;Biologie moléculaire des cancers

Immuno-Analyse et Biologie Specialisee

Volumn 19, Issue 1, 2004, Pages 13-22

  Bieche I ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Clinical applications; Proto oncogenes; Sporadic and familial cancers; Tumor suppressor genes

Indexed keywords

CARCINOGENESIS; GENE ACTIVATION; GENE INACTIVATION; GENETIC ANALYSIS; GENETIC MARKER; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; REVIEW;

EID: 1242315592     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2003.11.002     Document Type: Short Survey

References (10)

1. Tirkkonen M., Tanner M., Karhu R., Kallioniemi A., Isola J., Kallionier O.P. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer. 2:1998;177-184.
2. Jaallepalli P.V., Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat. Rev. Cancer. 1:2001;109-117.
3. Tycko B. Epigenetic gene silencing in cancer. J. Clin. Invest. 105:2000;401-407.
4. Perou C.M., Sorlie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature. 406:2000;747-752.
5. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
6. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer. 1:2001;46-54.
7. Van't Veer L.J., Dai H., Van De Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
8. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60:2000;4161-4166.
9. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 3:2002;137-144.
10. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer. 2:2002;657-672.